poisar

Stocks · News reference

JP Morgan Initiates Coverage On Kura Oncology with Overweight Rating, Announces Price Target of $30

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Insights

    Kura Oncology Q2 2026 Earnings Call Transcript

    On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts